SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 557.63 |
| Enterprise Value ($M) | 456.84 |
| Book Value ($M) | 178.95 |
| Book Value / Share | 2.88 |
| Price / Book | 3.12 |
| NCAV ($M) | 144.90 |
| NCAV / Share | 2.34 |
| Price / NCAV | 3.85 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.22 |
| Return on Assets (ROA) | -0.18 |
| Return on Equity (ROE) | -0.19 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 17.23 |
| Current Ratio | 17.23 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 154.22 |
| Assets | 188.27 |
| Liabilities | 9.32 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -50.25 |
| Net Income | -38.96 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -42.28 |
| Cash from Investing | 65.14 |
| Cash from Financing | -0.30 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Fmr Llc | 4.80 | -20.71 | |
| 13G/A | Lynx1 Capital Management LP | 9.30 | 15.80 | |
| 13G/A | Ra Capital Management, L.p. | 12.90 | 19.68 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 29,966 | 127,760 | 23.45 | |
| 32,951 | 204,562 | 16.11 | |
| 25,429 | 138,068 | 18.42 | |
| 48,609 | 103,203 | 47.10 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| FOLD – Amicus Therapeutics, Inc. | FULC – Fulcrum Therapeutics, Inc. |
| GANX – Gain Therapeutics, Inc. | HRMY – Harmony Biosciences Holdings, Inc. |
| HROW – Harrow, Inc. | |
Financial data and stock pages provided by
Fintel.io